E-resources
-
Brady, Christopher B., PhD; Gaziano, J. Michael, MD; Cxypoliski, Roberta A., MSN; Guarino, Peter D., PhD; Kaufman, James S., MD; Warren, Stuart R., PharmD; Hartigan, Pamela, PhD; Goldfarb, David S., MD; Jamison, Rex L., MD
American journal of kidney diseases, 09/2009, Volume: 54, Issue: 3Journal Article
Background Individuals with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) have high plasma total homocysteine (tHcy) levels, which may be a risk factor for cognitive impairment. Whether treatment with high-dose B vitamins to decrease high tHcy levels improves cognition in persons with kidney disease is unknown. Study Design Randomized controlled trial. Setting & Participants A substudy of 659 patients (mean age, 67.3 ± 11.7 years) who participated in a randomized double-blind clinical trial 5 years in duration conducted in 36 US Department of Veterans Affairs medical centers of the effect on all-cause mortality of vitamin-induced lowering of plasma tHcy level. 236 (35.8%) were treated by using dialysis (ESRD) and 423 (64.2%) had a Cockcroft-Gault estimated creatinine clearance of 30 mL/min or less (advanced CKD). All had high tHcy levels (≥15 μmol/L) at baseline. Cognitive assessments began during the follow-up period of the main trial 3 years after treatment began; participants subsequently were retested 1 year later to assess cognitive change. Intervention Daily high-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6 , and 2 mg of vitamin B12 ) or placebo. Outcomes Cognitive function at initial assessment and 1 year later. Measurements Telephone Interview of Cognitive Status–modified, supplemented with attention, working memory, and executive function tests. Results Initial cognitive function was impaired in approximately 19% of patients regardless of treatment assignment (vitamin or placebo) or kidney disease status (advanced CKD or ESRD). Treatment decreased tHcy levels by 26.7%. Unadjusted and adjusted analyses showed that treatment did not improve initial cognitive outcomes or affect subsequent cognitive status 1 year later. Limitations Cognitive assessments began after treatment was initiated; cognitive assessment was limited. Conclusion Treatment with high daily doses of B vitamins, which decreased tHcy levels, did not affect cognitive outcomes in patients with advanced CKD and ESRD.
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.